Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Rein Therapeutics, Inc. (RNTX)
Company Research
Source: Yahoo! Finance
AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that it has dosed the first patient in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. This milestone follows the FDA's recent clearance to resume the Phase 2 program and reflects Rein's successful efforts to address the Agency's requests and advance the trial. The Phase 2 study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, and impact to lung function and structure of LTI-03, an inhaled therapy intended to regulate multiple fibrosis pathways and preserve lung function. The study will enroll approximately 120 patients across placebo, low dose, and hi
Show less
Read more
Impact Snapshot
Event Time:
RNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNTX alerts
High impacting Rein Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNTX
News
- Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary FibrosisGlobeNewswire
- Rein Therapeutics (NASDAQ:RNTX) had its "hold" rating reaffirmed by analysts at Brookline Capital Management.MarketBeat
- Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at Citigroup Inc. to a "hold" rating.MarketBeat
- Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary FibrosisGlobeNewswire
- Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RNTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
RNTX
Analyst Actions
- 1/21/26 - Citigroup Inc.
RNTX
Sec Filings
- 2/19/26 - Form 8-K
- 2/13/26 - Form SCHEDULE
- 1/16/26 - Form 8-K
- RNTX's page on the SEC website